Tecan Group AG · SIX:TECN
Tecan — H1 2021 Earnings Presentation
26 slides from Tecan's earnings presentation, Aug 18, 2021
Slide 1: Half Year Results 2021
Zurich, August 18 2021 Half Year Results 2021 ANALYST & MEDIA CONFERENCE CALL
Slide 2: Speakers
Speakers Dr. Achim von Leoprechting, CEO Tania Micki, CFO
Slide 3: Agenda
Agenda FINANCIAL AND OPERATING HIGHLIGHTS FINANCIAL RESULTS OUTLOOK QUESTIONS AND ANSWERS 3
Slide 4: Financial Highlights H1 2021
Financial Highlights H1 2021 • Orders again grew significantly (+20.9% in LC); non-COVID-19 orders exceeded pandemic-related orders • Substantial sales growth of +47.5% in LC and +46.5% in CHF, on top of a strong performance in H1 2020 • Sales growth driven by continued significant pandemic-related
Slide 5: Operating Highlights H1 2021
Operating Highlights H1 2021 • Launch of new variants of the Fluent® Automation NEW FLUENT VARIANTS FOR KEY APPLICATIONS Workstation to solve specific needs in key research and diagnostic applications • Introduced new important reagent and digital offerings • Meeting the new requirements of the Euro
Slide 6: Agenda
Agenda FINANCIAL AND OPERATING HIGHLIGHTS FINANCIAL RESULTS OUTLOOK QUESTIONS AND ANSWERS 6
Slide 7: Order Entry and Sales Performance
H1 2021 Order Entry and Sales Performance ORDER ENTRY H1 2021 449.6 ORDER ENTRY H1 2021 VS. H1 2020 460 • +20.2% in CHF, +20.9% in LC 420 374.0 • Continued strong order entry for consumables to support the CHF (mio) 380 global fight against COVID-19, to a lesser extent for new 340 instruments 300 •
Slide 8: Segment Sales
H1 2021 Segment Sales SALES 260 250.4 2020 LIFE SCIENCES BUSINESS: 2021 240 • Sales up by 47.8% in CHF and 49.5% in LC 220 203.7 • Based on high order backlog at year-end 2020, continued CHF (mio) 200 180 169.4 strong revenue contribution from pandemic-related products 160 140.6 140 • Substantial re
Slide 9: Regional Sales Development
H1 2021 Regional Sales Development • Continued strong sales contribution from products supporting the COVID-19 response • Significant recovery in other application areas • Percentage development impacted by comparative basis of prior-year period Others EUROPE 1.4% • +38.3% in CHF, +36.1% in LC • Lif
Slide 10: Gross Profit
H1 2021 Gross Profit GROSS PROFIT (% = % OF SALES) GROSS PROFIT INCREASED TO CHF 224.5M 240 • CHF 78.4m or 53.7% above H1 2020 224.5 GROSS PROFIT MARGIN UP BY 230BPS Main effects contributing: 200 • (+) Product mix CHF (mio) • (+) Adjustment of Swiss pension plan (portion of) • (+) Price 160 47.6% 4
Slide 11: Cost Structure
H1 2021 Cost Structure OPERATING EXPENSES (% = % OF SALES) 128.2m OPERATING EXPENSES GREW ONLY AT ABOUT 140 (28.2%) HALF THE RATE COMPARED TO SALES 120 • Total operating expenses down by 520 bps, 103.5m (33.4%) driven by economies of scale 52.7 100 (16.0%) (11.6%) • Sales & Marketing grew less than
Slide 12: EBIT and EBITDA
H1 2021 EBIT and EBITDA EBIT AND EBITDA (IN CHF MILLIONS) 115.0 2020 REPORTED EBITDA GREW TO CHF 115.0M 120 97.8 2021 • CHF 54.8m or 91.1% above H1 2020 100 • (+) Improved gross profit margin (+230 bps) CHF (mio) 80 60.2 • (+) Adjustment of Swiss pension plan (assessing alternative 60 42.6 pension s
Slide 13: Segment Profitability
H1 2021 Segment Profitability EBIT (IN CHF MILLIONS) 2020 LIFE SCIENCES BUSINESS: 70 63.1 60 2021 • EBIT margin at 22.8% 49.2 50 • Factors contributing include: CHF (mio) 40 26.3 • (+) Volume effect 30 22.5 20 • (+) Margin contribution from consumables business 10 • (-) Higher freight, logistics, in
Slide 14: Net Profit
H1 2021 Net Profit NET PROFIT NET PROFIT MORE THAN DOUBLED 82.6 • CHF 46.6M or 129.1% above H1 2020 80 70 NET PROFIT MARGIN AT 18.2% • Main factors contributing: 60 • (+) EBIT up by CHF 55.2m CHF (mio) 50 • (-) Financial result • (-) Tax rate of 13.1% (H1 2020: 12.8%) 40 36.0 29.2 30 26.0 25.3 20 10
Slide 15: Basic Earnings per Share
H1 2021 Basic Earnings per Share BASIC EARNINGS PER SHARE EARNINGS PER SHARE AT CHF 6.88 7 6.88 NUMBER OF SHARES OUTSTANDING ON JUNE 30, 2021: 12.0M (JUNE 30, 2020: 11.9M) 6 5 CHF (mio) 4 48.8% 49.5% 3.02 48.8% 49.5% 3 2.49 2.25 2.14 2 1 0 2017 2018 2019 2020 2021 15
Slide 16: Cash Flow
H1 2021 Cash Flow +111.4 -13.6 -31.1 215.1 148.4 +66.7m CHF (mio) Cash at the end from Operations from Investments from Financing1 Cash at the end of December 2020 of June 2021 CASH FLOW FROM OPERATIONS OF CHF 111.4M (H1 2020: CHF 82.8M) • Cash conversion of 24.5% of sales • Days Sales Outstanding a
Slide 17: Key Figures
H1 2021 Key Figures 2020 2021 Δ IN % Order Entry (in CHF mio) 374.0 449.6 +20.2% Sales (in CHF mio) 310.0 454.0 +46.5% Sales in local currencies (in CHF mio) 307.8 454.0 +47.5% Gross Profit (in CHF mio) 146.1 224.5 +53.7% in % of sales 47.1% 49.4% R&D (in CHF mio) 25.3 31.1 +22.9% in % of sales 8.2%
Slide 18: Agenda
Agenda FINANCIAL AND OPERATING HIGHLIGHTS FINANCIAL RESULTS OUTLOOK QUESTIONS AND ANSWERS 18
Slide 19: Acquisition of Paramit Corporation
Acquisition of Paramit Corporation TECAN TO EXPAND COMMERCIAL REACH, CAPABILITIES AND GEOGRAPHIC FOOTPRINT • Paramit Corporation, a leading OEM developer and manufacturer of medical devices and life sciences instruments • Acquisition successfully completed at beginning of August • Adds complementary
Slide 20: Acquisition Significantly Expands Total Addressable Market
Acquisition Significantly Expands Total Addressable Market ADDING A 4TH AND 5TH STRATEGIC GROWTH VECTOR MEDICAL DEVICES LIFE SCIENCE RESEARCH IN-VITRO DIAGNOSTICS (MEDICAL MECHATRONICS) >55 BN USD >60 BN USD >100 BN USD (TAM: 4-5 BN) (TAM: ≈4 BN) (TAM: 13-15 BN) Implants & Consumables + Instruments
Slide 21: Strong Presence in North America and Asia
Strong Presence in North America and Asia COMBINED ENTITY TO BENEFIT FROM COMPLEMENTARY GEOGRAPHIC FOOTPRINT 21
Slide 22: Compelling Financial Profile
Compelling Financial Profile • Acquisition will be immediately and significantly accretive to earnings per share (EPS) • In full year 2021, Paramit is expected to generate around USD 280m in sales (CHF 257m) and around USD 50m EBITDA (CHF 46m), before acquisition-related cost • Acquisition will prov
Slide 23: Raising Financial Outlook for 2021
Raising Financial Outlook for 2021 OUTLOOK 2021 – GENERAL ASSUMPTIONS • Based on strong business momentum and positive market environment, raising organic outlook for 2021 • The development of demand for products related to COVID-19 still remains subject to uncertainty for the remainder of the year
Slide 24: Q&A
Slide 25: Contact and Events
Contact and Events CONTACT Martin Braendle Senior Vice President, Corp. Communications & IR Phone: +41 (0) 44 922 84 30 investor@tecan.com www.tecan.com NEXT EVENTS 2022 March 15: Full Year Results and Annual Report 2021 April 12: Annual Shareholder Meeting 25
Slide 26: Tecan – Who we are
Tecan – Who we are Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the lif